These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 34434610)

  • 41. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 42. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
    Lee H; Ahn S; Maity R; Leblay N; Ziccheddu B; Truger M; Chojnacka M; Cirrincione A; Durante M; Tilmont R; Barakat E; Poorebrahim M; Sinha S; McIntyre J; M Y Chan A; Wilson H; Kyman S; Krishnan A; Landgren O; Walter W; Meggendorfer M; Haferlach C; Haferlach T; Einsele H; Kortüm MK; Knop S; Alberge JB; Rosenwald A; Keats JJ; Rasche L; Maura F; Neri P; Bahlis NJ
    Nat Med; 2023 Sep; 29(9):2295-2306. PubMed ID: 37653344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
    Zhang X; Zhang H; Lan H; Wu J; Xiao Y
    Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
    Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y
    Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.
    Xu J; Wang Q; Xu H; Gu C; Jiang L; Wang J; Wang D; Xu B; Mao X; Wang J; Wang Z; Xiao Y; Zhang Y; Li C; Zhou J
    J Hematol Oncol; 2018 Oct; 11(1):128. PubMed ID: 30348186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
    Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
    Wu JF; Dhakal B
    J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
    An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
    Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
    Sun Y; Yang XN; Yang SS; Lyu YZ; Zhang B; Liu KW; Li N; Cui JC; Huang GX; Liu CL; Xu J; Mi JQ; Chen Z; Fan XH; Chen SJ; Chen S
    Signal Transduct Target Ther; 2023 Dec; 8(1):445. PubMed ID: 38062078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GPRC5D-Targeted CAR T Cells for Myeloma.
    Mailankody S; Devlin SM; Landa J; Nath K; Diamonte C; Carstens EJ; Russo D; Auclair R; Fitzgerald L; Cadzin B; Wang X; Sikder D; Senechal B; Bermudez VP; Purdon TJ; Hosszu K; McAvoy DP; Farzana T; Mead E; Wilcox JA; Santomasso BD; Shah GL; Shah UA; Korde N; Lesokhin A; Tan CR; Hultcrantz M; Hassoun H; Roshal M; Sen F; Dogan A; Landgren O; Giralt SA; Park JH; Usmani SZ; Rivière I; Brentjens RJ; Smith EL
    N Engl J Med; 2022 Sep; 387(13):1196-1206. PubMed ID: 36170501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.
    García-Guerrero E; Rodríguez-Lobato LG; Sierro-Martínez B; Danhof S; Bates S; Frenz S; Haertle L; Götz R; Sauer M; Rasche L; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Prommersberger SR
    Haematologica; 2023 Feb; 108(2):568-580. PubMed ID: 36722406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
    Xu J; Ming X; Wang C; Xu B; Xiao Y
    Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
    Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
    Front Immunol; 2019; 10():1613. PubMed ID: 31379824
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
    Elnaggar M; Agte S; Restrepo P; Ram M; Melnekoff D; Adamopoulos C; Stevens MM; Kappes K; Leshchenko V; Verina D; Jagannath S; Poulikakos PI; Parekh S; Laganà A
    J Hematol Oncol; 2022 Aug; 15(1):109. PubMed ID: 35978321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.